Director Share Sale To Institutional Funds Manager
Filed with ASX · · 2 pages · English
❖ Share Sale of 5,000,000 RHY Shares @ $1.30 per share by Executive Chairman; ❖ Exclusive Sale to leading, domestic, institutional funds manager; and ❖ No further share sales envisaged for the foreseeable future. Transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) confirms an exclusive share sale conducted by the Executive Chairman to a s
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- RHY Advances Platform Expansion with Other Cancers
- Application for quotation of securities - RHY
- Completion of Final TGA Submission Step to Approve ColoSTAT
- Rhythm Closes Final Clinical Trial Site
- Appendix 4C - quarterly
Later from Rhythm Biosciences
- Rhythm Receives $2.7m R&D Tax Incentive
- ColoSTAT Authorised For Sale In New Zealand
- Healthcare Conference Investor Presentation
- RHY 2022 AGM Presentation
- MST Access Financial Diagnostics Presentation
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences